Cell & Gene Therapies

Event inaugurating the new plant in Spain in June © VIVEbiotech

Special Edition: Meeting demand for viral vectors

VIVEbiotech looks to overcome challenges related to LVV production

By Jane Byrne

VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....

Pic:getty/richarddrury

mRNA and beyond: Opportunities for US biologics

By Staff reporter

The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.

© GettyImages/Andrew Brookes

Generate looks to in-house stem cell manufacturing

By Jane Byrne

Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.

© GettyImages/janiecbros

EU go-ahead for bluebird bio gene therapy for CALD

By Jane Byrne

Bluebird’s Lenti-D, or elivaldogene autotemcel, has won approval from the European Commission to treat children with a rare neurodegenerative disease called early cerebral adrenoleukodystrophy (CALD).

© GettyImages/FlashMovie

NPD Gallery: Technology Insider

By Jane Byrne

We report on some of the latest biopharma industry targeted new releases in terms of technological innovation.

© GettyImages/koto_feja

Dispatches from Bio Digital 2021

Mogrify looks to transform cell therapy development

By Jane Byrne

Biotech, Mogrify, recently closed a Series A financing of US$17m, bringing the total raised to US$33m in the round, with the investment set to support the advancement of the company’s immuno-oncology and ophthalmology programs.

© GettyImages/Isaac74

Coriolis expands ATMP facilities to advance formulation

By Ben Hargreaves

Coriolis Pharma has announced a 7,800-meter-square expansion to a building situated in Munich, Germany, where the company is headquartered, that will host formulation development for advanced therapeutic medicine products (ATMPs).

© GettyImages/metamorworks

Gamma Biosiences takes majority stake in Mirus Bio

By Jane Byrne

Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US.

Chicago emerging as life science and biopharma hub

Chicago emerging as a life science and biopharma hub

By Jane Byrne

Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth,...

© GettyImages/Dilok Klaisataporn

PPD adds cell and gene therapy testing capabilities to Irish site

By Jane Byrne

US contract research organization, PPD Inc, is expanding its Athlone, Ireland, GMP laboratory, significantly increasing the size of its current facility and adding cell and gene therapy (CGT) testing to the operation’s portfolio of services.